Compare Cassava Sciences Inc (FLNA) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Williams-Sonoma, Inc. — how do they compare? Cassava Sciences Inc trades at $1.1 (market cap $53.14M), while Williams-Sonoma, Inc. trades at $223.99 (market cap $26.24B). The key difference: Williams-Sonoma, Inc. is far larger — about 493.8× Cassava Sciences Inc's market cap, and Williams-Sonoma, Inc. pays a 1.36% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | WSM | |
|---|---|---|
Market Cap | $53.14M | $26.24B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $240.06 |
52-Week Low | $1.09 | $165.01 |
Enterprise Value | -$33.43M | $27.08B |
Dividend Yield | — | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Williams-Sonoma (WSM) trades at $227.86, up 3.41% with a bullish technical signal. The stock shows strong profitability with a 13.81% net income margin and 54.01% ROE, supported by recent earnings beats. Valuation metrics include a P/E of 24.98 and P/S of 3.45. Recent news highlights brand collaborations and dividend payouts, while cash flow trends indicate operational resilience despite net outflows.
Outlook remains positive with analyst consensus at Buy (28.57%) and a $215.22 price target, though risks include revenue volatility and competitive pressures. The stock's momentum is bolstered by consistent earnings performance, but investors should monitor macroeconomic headwinds affecting discretionary spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
